The experimental treatment uses lipid nanoparticles, or LNPs, microscopic spheres made from fat-like molecules that can transport therapeutic cargo into cells. The Penn researchers engineered an LNP formulation to deliver messenger RNA encoding the tumor-suppressor protein p53 alongside ciclopirox, an FDA-approved antifungal drug with reported anticancer and immune-modulating activity. Their findings, published in Advanced Materials, indicate that the combined treatment can reduce tumor growth and extend survival in animal models, including models in which tumors resist p53-based therapy.

The rationale for targeting p53 is rooted in the genetics of oral cancer. More than 70% of oral squamous cell carcinoma cases involve mutations in the TP53 gene, which normally produces p53, a protein that helps detect cellular damage and either halt cell division or initiate programmed cell death. When p53 is disabled, abnormal cells can continue multiplying, accumulate additional mutations, and evade mechanisms that would ordinarily eliminate them. Delivering p53 messenger RNA offers a temporary way to instruct tumor cells to produce functional p53 without permanently altering their DNA.

Messenger RNA, however, is fragile and difficult to deliver. It can be rapidly degraded in the body and may fail to enter tumor cells in sufficient quantities. LNPs help solve this problem by packaging the RNA inside a protective structure that can interact with cell membranes and release its cargo after uptake. The Penn team designed a specialized formulation intended to improve delivery into oral cancer cells, a key challenge because the success of an mRNA therapy depends not only on the genetic message but also on whether that message reaches the right cells.

The second component, ciclopirox, gives the approach a complementary mechanism. Rather than relying solely on restoration of a tumor-suppressor pathway, the drug can contribute direct chemotherapeutic effects while also influencing the immune environment surrounding the tumor. The researchers found that p53 and ciclopirox together acted through multiple biological routes, killing cancer cells while making the tumor microenvironment less immunosuppressive. This is important because tumors are not simply masses of malignant cells; they also contain immune cells and signaling networks that can suppress an effective attack.

Among the cells affected may be tumor-associated macrophages, immune cells that can either help eliminate cancer or, under the influence of a tumor, support its growth and shield it from immune destruction. The study suggests that the combined treatment may reprogram these macrophages, shifting them away from a tumor-protective state. The researchers emphasize that the precise mechanism remains unresolved and that the proposed pathway will require further confirmation. Still, the possibility of converting the tumor’s immune surroundings from an obstacle into an ally is central to the platform’s chemoimmunotherapy design.

The treatment may also benefit from the physical accessibility of oral tumors. Because many oral cancers can be reached locally, an LNP-based therapy could potentially be administered in a way that concentrates treatment near the tumor while limiting exposure to healthy tissues. At the same time, local treatment could stimulate a broader immune response capable of recognizing malignant cells elsewhere in the body. That prospect is particularly significant for oral squamous cell carcinoma, which can recur or spread to regional lymph nodes and distant sites. The current work, however, remains preclinical and does not establish that the therapy is safe or effective in people.

In animal experiments, the LNP combination reduced tumor burden and prolonged survival, including in aggressive models described as resistant to p53 therapy. The dual-payload design could be valuable because tumors differ substantially from one patient to another. If one drug encounters a resistance mechanism, the second may continue to act through a separate pathway. Rather than developing a separate treatment for every mutation, the researchers envision a tunable delivery system in which the therapeutic cargo can be adjusted to match the biology of different tumors.

The Penn team plans to refine the nanoparticles to improve targeting and delivery precision, test additional drug combinations, and explore alternative routes of administration. Future studies will also use more complex preclinical models that better reflect the genetic diversity of human tumors. Such work will be essential before clinical testing, particularly because earlier efforts to use p53 as a cancer therapy have often been undermined by tumor heterogeneity and resistance. The researchers say the platform could eventually support customizable nanotherapies, but substantial questions about dosing, biodistribution, immune effects, manufacturing, and safety must still be answered.

The study illustrates how nanotechnology, RNA biology, cancer pharmacology, and oral medicine are converging around a disease in urgent need of new options. By combining a genetic therapy with a small-molecule drug in a single carrier, the researchers are attempting to make cancer treatment more adaptable than conventional single-agent strategies. The results do not yet represent a treatment available to patients, but they provide preclinical evidence that an LNP can simultaneously restore a damaged tumor-suppressor function, deliver a second anticancer compound, and reshape the immune landscape of oral cancer.

Subject of Research: Animals

Article Title: Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy

News Publication Date: 14 July 2026

Web References: https://doi.org/10.1002/adma.73721; https://mitchell-lab.seas.upenn.edu/about/; https://www.dental.upenn.edu/faculty/anh-d-le/

References: Advanced Materials, DOI: 10.1002/adma.73721

Keywords: Oral squamous cell carcinoma, oral cancer, lipid nanoparticles, mRNA therapy, p53, ciclopirox, cancer immunotherapy, chemoimmunotherapy, drug delivery, nanomedicine

The novelty of the approach resides in the encapsulation of miR-199a into biocompatible gold nanoparticles acting as precise delivery vehicles. Gold nanoparticles have emerged in the last decade as promising vectors due to their unique physicochemical properties, including biocompatibility, resistance to metabolic degradation, and ease of surface modification. These characteristics allow them to navigate the biological milieu effectively, ensuring that the therapeutic payload reaches the intracellular environment of HCC cells with minimal off-target effects. The loading of miR-199a onto such nanoparticles aims to circumvent several challenges faced by free microRNA, such as rapid degradation by nucleases and insufficient cellular uptake.

The researchers employed rigorous in vitro experimentation to evaluate the impact of miR-199a-loaded gold nanoparticles on cultured hepatocellular carcinoma cells. Cell viability assays revealed a significant reduction in tumor cell proliferation upon treatment, coupled with evidence of increased apoptosis. This indicates that the miR-199a not only inhibited cancer cell growth but actively induced programmed cell death pathways, which are often dysregulated in malignancies. These findings resonate strongly with existing literature emphasizing the tumor suppressor role of miR-199a in multiple cancer types, yet the use of gold nanoparticles amplifies its therapeutic availability and functional stability.

At the molecular level, the study delved into the mechanistic pathways through which miR-199a exerts its anticarcinogenic effects. The microRNA is known to target key oncogenes and signaling molecules involved in hepatocellular carcinogenesis, including those regulating cell cycle progression, angiogenesis, and metastasis. The nanoparticle-mediated delivery intensified the downregulation of these critical factors, as validated by quantitative PCR and Western blot analyses. Such precise molecular interference underscores the therapeutic potential of combining nanotechnology with RNA-based interventions to achieve targeted anti-cancer strategies.

This work also highlights the biocompatibility and minimal cytotoxicity of the gold nanoparticle constructs themselves, an essential consideration for clinical translation. Comprehensive characterization confirmed that the gold nanoparticle carriers did not induce significant toxicity in non-tumorigenic hepatocyte models, thereby suggesting a favorable safety profile. This contrasts with many conventional chemotherapeutic agents, notorious for their off-target organ toxicity and debilitating side effects, further bolstering the appeal of this nanoformulation as a viable therapeutic candidate.

Moreover, the research team optimized the physicochemical properties of the nanoparticles, including size, surface charge, and miRNA loading efficiency, to maximize cellular uptake and therapeutic output. Transmission electron microscopy and dynamic light scattering analyses confirmed the uniformity and stability of the nanoscale complexes. Such meticulous engineering ensures that the nanoparticles have optimal circulation times and efficient internalization by HCC cells, mechanisms critical for the success of nano-delivered therapies in clinical settings.

Another remarkable aspect of this study is the potential for customization and versatility of the gold nanoparticle platform. The surface of these nanoparticles can be functionalized with ligands or antibodies targeting specific receptors overexpressed on HCC cells, allowing a precision medicine approach to further improve delivery specificity. This opens new avenues for combination therapies where miR-199a-based interventions could be co-administered with other molecular agents or chemotherapeutics to heighten anticancer efficacy while minimizing systemic toxicity.

While the presented data are currently limited to in vitro settings, the implications for in vivo applications and eventual clinical translation are promising. The next logical steps involve validating these findings in animal models of hepatocellular carcinoma, where pharmacokinetic and pharmacodynamic profiles, biodistribution, and immune responses can be thoroughly assessed. Success at this stage could pave the way for early-phase human trials targeting unresectable or metastatic HCC, conditions desperately in need of improved therapeutic modalities.

The integration of nanotechnology and RNA interference mechanisms exemplified in this study aligns with the broader trend within oncology research toward more targeted, less invasive, and highly effective treatment paradigms. As molecular understanding of cancer biology deepens, leveraging natural regulatory molecules such as microRNAs, delivered through sophisticated carriers, could redefine therapeutic strategies and improve patient outcomes. The combination of gold nanoparticles with miR-199a exemplifies this cutting-edge convergence of disciplines, offering hope for patients with a historically poor prognosis.

Furthermore, the research offers valuable insights into overcoming the challenges associated with microRNA therapeutics, which have thus far hindered clinical application. Stability in circulation, avoidance of immune clearance, and efficient cytoplasmic release are major barriers. The use of gold nanoparticles addresses these by shielding the microRNA from enzymatic degradation, facilitating endosomal escape, and achieving sustained intracellular presence. Such technological innovations are crucial for realizing the full potential of RNA-based medicines.

This study also adds to the growing evidence underscoring the role of miRNAs as central regulatory hubs in cancer biology, capable of modulating multiple oncogenic pathways simultaneously. Unlike single-target drugs, miRNAs offer a systems-level approach to cancer treatment, potentially reducing the likelihood of therapeutic resistance. Delivering miR-199a via gold nanoparticles thus represents a leap forward in harnessing this capability with enhanced robustness and specificity.

The investigation acknowledges current limitations, including the complexity of the tumor microenvironment and the heterogeneity of HCC tumors, which may influence therapeutic effectiveness in vivo. Nevertheless, the platform’s adaptability and modular nature allow for future refinement, including targeting multiple microRNA species or integrating stimuli-responsive release mechanisms. Such strategies could further optimize therapeutic efficacy and minimize collateral damage to healthy tissues.

By rectifying previous inaccuracies, the authors have provided a meticulous correction that enhances the clarity and accuracy of the data interpretation, reinforcing the reliability of their findings. The publication of this correction exemplifies the scientific community’s commitment to transparency and reproducibility, reinforcing confidence in the reported results and fostering further research in this exciting domain.

In conclusion, the demonstration of potent anticarcinogenic effects of miR-199a-loaded gold nanoparticles against hepatocellular carcinoma cells marks a pivotal step forward in the quest for novel, efficacious cancer treatments. This innovative strategy capitalizes on the intersection of nanotechnology and RNA biology to address critical challenges in cancer therapy. As research progresses toward more complex biological models, the promise of translating these findings into clinical reality holds immense potential for improving prognosis and quality of life for patients battling hepatocellular carcinoma worldwide.

Subject of Research: Anticarcinogenic effects of miR-199a delivered via gold nanoparticles on hepatocellular carcinoma in vitro.

Article Title: Correction: Anticarcinogenic effects of miR-199a-loaded gold nanoparticles on hepatocellular carcinoma: in vitro study.

Article References:
Achy, S., Moustafa, M.E., Fouad, M., et al. Correction: Anticarcinogenic effects of miR-199a-loaded gold nanoparticles on hepatocellular carcinoma: in vitro study. Sci Rep 16, 18694 (2026). https://doi.org/10.1038/s41598-026-57367-8

Image Credits: AI Generated